* HELLO *
AND WELCOME
A DEDICATED COMPANY, WITH SOLID CREDENTIALS & AND AN EXTENSIVE FOOTPRINT IN PHARMA
READ MOREOUR WORK
HEALTH
IS EVERYTHING
WE ARE PART OF THE SOLUTION WHEN IT COMES TO UNIVERSAL ACCESS TO GOOD QUALITY MEDS
NEWSSTORIES
PHARMA
MARKETS
WE UNDERSTAND HOW TO GET YOUR PRODUCTS TO MARKET EFFICIENTLY AND WITH EASE
LEARN MOREGALLERY

Our Services

Clinical Research Development

At Pharma Strategies, we ensure that our clients optimally balance time, risk and cost in order to maximize the potential of a product…. Read More

Innovation Management

It is our observation that Pharma’s innovation focus remains on products and business models, and as such, Pharma Strategies …. Read More

Product Development Strategy

At Pharma Strategies, we combine clinical and commercial insights to transform your product development. Read More

New Market Access

Everybody’s talking about market access. But far fewer appear able to define it. In the competitive world of pharmaceutical … Read More

Business Development

Developing your business – through partnering, acquisition, licensing – and expanding your portfolio: a big ask in tough … Read More

Marketing & Education

Pharma Strategies is heavily involved in the provision of Marketing Excellence and Continuous Medical Education Read More

Why us?

We have the tools

We have all the tools necessary to execute complex tasks so that you dont have to!

Certified Experience

We are certfied industry leaders with an established footprint spanning many years.

Industry Experience

Our collective extensive experience and knowledge is over 30 years strong.

Smart Partnerships

We believe in smart partnerships. Therefore, our solutions are distinguished, tried, and tested.

Stakeholder Relationships

Our work spans across both the public and private sectors alike. We understand the dynamics of each.

Great Support

Our team is brilliant! We are here for the long haul & value each relationship, old and new.

Some of our Products

Latest News

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will evaluate efficacy, safety, and tolerability of OAV-101 I…

Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer

Novartis today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer. NIS793 is a potential first in class …

© Copyright - Pharma Strategies | Zimbabwe